Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach

被引:3
|
作者
Dulai, Parambir S. [1 ]
Siegel, Corey A. [2 ]
机构
[1] Univ Calif San Diego, San Diego, CA 92103 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
关键词
Crohn's disease; ulcerative colitis; risk; adverse events; inflammatory bowel disease; infections; NONMELANOMA SKIN-CANCER; FACTOR-ALPHA ANTAGONISTS; CROHNS-DISEASE; INCREASED RISK; HEPATITIS-B; CLOSTRIDIUM-DIFFICILE; COMBINATION THERAPY; OPPORTUNISTIC INFECTIONS; MAINTENANCE THERAPY; RECEIVE THIOPURINES;
D O I
10.2174/1389450118666170525114939
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). Alongside this shift in therapeutic options has come an opportunity to personalize treatment decisions based on individual patient profiles and preferences. One of the most important aspects of therapy in IBD is treatment related risk, and an opportunity exists to personalize therapy through optimization of drug safety profiles in individual patients. In this review we discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
引用
收藏
页码:740 / 747
页数:8
相关论文
共 50 条
  • [11] Inflammatory bowel disease: towards a personalized medicine
    Flamant, Mathurin
    Roblin, Xavier
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11 : 1 - 15
  • [12] Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease
    Mosli, Mahmoud H.
    Sandborn, William J.
    Kim, Richard B.
    Khanna, Reena
    Al-Judaibi, Bandar
    Feagan, Brian G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (07) : 994 - 1004
  • [13] Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
    Hahn, Gustavo Drugg
    LeBlanc, Jean-Frederic
    Golovics, Petra Anna
    Wetwittayakhlang, Panu
    Qatomah, Abdulrahman
    Wang, Anna
    Boodaghians, Levon
    Liu Chen Kiow, Jeremy
    Al Ali, Maryam
    Wild, Gary
    Afif, Waqqas
    Bitton, Alain
    Lakatos, Peter Laszlo
    Bessissow, Talat
    WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (33) : 4823 - 4833
  • [14] Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments
    Lee, Scott D.
    Shivashankar, Raina
    Quirk, Daniel
    Zhang, Haiying
    Telliez, Jean-Baptiste
    Andrews, John
    Marren, Amy
    Mukherjee, Arnab
    Loftus, Edward V., Jr.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (03) : 195 - 206
  • [15] Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?
    Yzet, Clara
    Tse, Stacy S.
    Kayal, Maia
    Hirten, Robert
    Colombel, Jean-Frederic
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (01) : 57 - 63
  • [16] Personalized Nutrition for Inflammatory Bowel Disease
    Collins, Colm B.
    Roche, Helen M.
    CROHNS & COLITIS 360, 2020, 2 (03)
  • [17] Treatments of inflammatory bowel disease toward personalized medicine
    Ki-Uk Kim
    Jisu Kim
    Wan-Hoon Kim
    Hyeyoung Min
    Chang Hwan Choi
    Archives of Pharmacal Research, 2021, 44 : 293 - 309
  • [18] Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Park, Su Hyun
    Park, Sang Hyoung
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (08) : 1434 - 1445
  • [19] Updates in therapeutic drug monitoring in inflammatory bowel disease
    Lodhia, Nilesh
    Rao, Shanti
    WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (21) : 2282 - 2290
  • [20] Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease A Review for Nurses
    Morvillo, Cynthia
    Vinci, Katherine
    Hedenschoug, Lauren
    Mancini, Leah
    Mize, Carrie
    Tugg, Kayce
    Stein, Steven
    GASTROENTEROLOGY NURSING, 2020, 43 (04) : E159 - E171